The global genomics market is poised to expand significantly, rising from $39.5 billion in 2024 to $157.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 16.6%. Simultaneously, the human microbiome market is forecasted to surge from $814 million in 2024 to over $4.2 billion by 2030, with a CAGR of 31.5%. These projections highlight the revolutionary impact of genomic and microbiome sciences on personalized medicine.
On December 11, 2024, CE-Ventures, the venture capital arm of Crescent Enterprises, will host a symposium titled “The Microbiome and Genomics Revolution: Personalising Medicine for Health and Longevity” at the Palace Downtown, Dubai. This event aims to promote personalized and preventive healthcare by convening top experts to explore the applications of microbiome science and genomics in tailored medical treatments. The symposium will serve as a collaborative forum to discuss the integration of microbiome science, genomics, and artificial intelligence in addressing global health issues. Key topics include chronic disease management, longevity, immune health, and the ethical implications of equitable access to new healthcare technologies.
Tushar Singhvi, Deputy CEO and Head of Investments at Crescent Enterprises, emphasized the significance of this growth: “As we stand on the brink of a healthcare revolution, the convergence of microbiome science and genomics presents transformative opportunities to personalize treatments and enhance health outcomes. This symposium underscores Crescent Enterprises’ commitment to fostering collaboration and translating scientific breakthroughs into practical solutions that benefit communities globally.”
CE-Ventures has consistently demonstrated its dedication to advancing healthcare innovation through strategic investments. Companies like Freya Biosciences, specializing in microbial immunotherapies for reproductive health, and Exeliom Biosciences, a leader in leveraging microbiome science for chronic disease interventions, exemplify this commitment. These investments reflect CE-Ventures’ vision of bridging the gap between cutting-edge research and real-world healthcare applications.
The symposium will feature global experts, including Prof. Nicholas Arpaia, Associate Professor of Microbiology and Immunology at Columbia University; Dr. Caleb Bell, Founding President and Executive Director of the Corundum Convergence Institute; Dr. Aashish Jha, Assistant Professor of Biology at New York University Abu Dhabi; Dr. James Kinross, Senior Lecturer in Colorectal Surgery at Imperial College London; Enej Kuscer, Co-founder and CEO of NU; Nik Sharma, Co-founder and CEO of BioCortex; Dr. Richard Siow, Director of Ageing Research at King’s College London; and Dr. Rob Knight, Professor of Pediatrics and Computer Science & Engineering at the University of California, San Diego. Their collective expertise highlights the event’s focus on pioneering advancements in microbiome and genomics research.
“This symposium marks a crucial step in advancing healthcare innovation and addressing the challenges of contemporary medicine. By uniting leading experts and stakeholders, we are promoting collaboration and scientific breakthroughs that will improve health outcomes, enhance quality of life, and support sustainable healthcare systems,” added Tushar.
In line with the UAE’s Year of Sustainability 2024, the symposium underscores the nation’s commitment to sustainable development across all sectors, including healthcare. Hosting this event in Dubai reinforces the UAE’s vision to create long-term, equitable healthcare solutions and foster global collaboration to achieve net-zero emissions by 2050.
With the global microbiome market expected to expand and healthcare spending in the Middle East projected to surpass $200 billion by 2025, this symposium represents a critical juncture in advancing personalized healthcare solutions. By bringing together industry pioneers, investors, and researchers, the event aims to address key healthcare challenges, such as chronic disease management and longevity, and shape a future where cutting-edge innovation transforms global health outcomes.
Source link: https://www.khaleejtimes.com
